GlassScriptPhysician profile
Dimitri Belkin
NPI 1861856155
$2,123.90
in general payments reported to CMS, 2019-2025
20 companies · $1,386 in 2025
The $1,386 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.92 · 2023: $330 · 2024: $394 · 2025: $1,386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,080 · Education: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,079.98 |
| Education | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $466.40 | 2024-2025 | |
| Janssen Biotech, INC. | $235.12 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $225.49 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $216.72 | 2024-2025 | Livdelzi |
| Regeneron Healthcare Solutions, INC. | $134.35 | 2023-2025 | Dupixent |
| Boston Scientific Corporation | $125.57 | 2025 | Wallflex Duodenal |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.05 | 2023-2025 | Xifaxan |
| Fujifilm Healthcare Americas Corporation | $112.79 | 2023 | Fujifilm |
| Phathom Pharmaceuticals, INC. | $107.53 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $63.20 | 2025 | Iqirvo |
| Lilly USA, LLC | $60.94 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $55.09 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $37.81 | 2023 | Dificid |
| Celgene Corporation | $34.16 | 2023-2024 | Zeposia |
| Pfizer INC. | $31.00 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $28.11 | 2025 | |
| Ferring Pharmaceuticals INC. | $19.52 | 2023 | Rebyota |
| Madrigal Pharmaceuticals | $19.20 | 2025 | Rezdiffra |
| Lucid Diagnostics INC. | $15.93 | 2023 | |
| Apollo Endosurgery US INC | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dimitri Belkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.